[go: up one dir, main page]

WO2014068463A3 - Compositions and methods for the treatment of inflammation and metabolic disorders - Google Patents

Compositions and methods for the treatment of inflammation and metabolic disorders Download PDF

Info

Publication number
WO2014068463A3
WO2014068463A3 PCT/IB2013/059662 IB2013059662W WO2014068463A3 WO 2014068463 A3 WO2014068463 A3 WO 2014068463A3 IB 2013059662 W IB2013059662 W IB 2013059662W WO 2014068463 A3 WO2014068463 A3 WO 2014068463A3
Authority
WO
WIPO (PCT)
Prior art keywords
inflammation
treatment
compositions
methods
metabolic disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2013/059662
Other languages
French (fr)
Other versions
WO2014068463A2 (en
Inventor
Mahesh Kandula
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2014068463A2 publication Critical patent/WO2014068463A2/en
Publication of WO2014068463A3 publication Critical patent/WO2014068463A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of inflammation and metabolic disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of diabetes, lipid disorders, cardiovascular diseases, pain and inflammation.
PCT/IB2013/059662 2012-11-03 2013-10-25 Compositions and methods for the treatment of inflammation and metabolic disorders Ceased WO2014068463A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN4601CH2012 2012-11-03
IN4601/CHE/2012 2012-11-03

Publications (2)

Publication Number Publication Date
WO2014068463A2 WO2014068463A2 (en) 2014-05-08
WO2014068463A3 true WO2014068463A3 (en) 2014-07-31

Family

ID=50628194

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2013/059662 Ceased WO2014068463A2 (en) 2012-11-03 2013-10-25 Compositions and methods for the treatment of inflammation and metabolic disorders

Country Status (1)

Country Link
WO (1) WO2014068463A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014083476A2 (en) * 2012-11-27 2014-06-05 Mahesh Kandula Compositions and methods for the treatment of metabolic and lipid disorders
WO2014087307A2 (en) * 2012-12-04 2014-06-12 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome and diabetes
WO2014087323A2 (en) * 2012-12-06 2014-06-12 Mahesh Kandula Compositions and methods for the treatment of autoimmune and chronic metabolic diseases
US11173135B2 (en) 2016-03-17 2021-11-16 Thiogenesis Therapeutics, Inc. Compositions for controlled release of cysteamine and systemic treatment of cysteamine sensitive disorders
EP3529379B1 (en) * 2016-10-24 2022-05-18 Nederlandse Organisatie voor toegepast- natuurwetenschappelijk onderzoek TNO System and method for implementing meal selection based on vitals, genotype, and phenotype
ES3024932T3 (en) * 2017-09-20 2025-06-05 Thiogenesis Therapeutics Inc Compounds for the treatment of cysteamine sensitive disorders
WO2025194075A1 (en) * 2024-03-14 2025-09-18 Thiogenesis Therapeutics, Inc. Pharmaceutically acceptable salts of cysteamine-pantetheine disulfide and uses thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2351739A1 (en) * 1998-08-28 2000-03-09 Gryphon Sciences Polyamide chains of precise length, methods to manufacture them and their conjugates with proteins
US20010002404A1 (en) * 1996-05-22 2001-05-31 Webb Nigel L. Fatty acid-pharmaceutical agent conjugates
US6919076B1 (en) * 1998-01-20 2005-07-19 Pericor Science, Inc. Conjugates of agents and transglutaminase substrate linking molecules
US20100184730A1 (en) * 2008-07-08 2010-07-22 Vu Chi B Fatty Acid Acylated Salicylates and Their Uses
WO2011106688A1 (en) * 2010-02-26 2011-09-01 Catabasis Pharmaceuticals, Inc. Bis-fatty acid conjugates and their uses
US20120184585A1 (en) * 2009-09-01 2012-07-19 Catabasis Pharmaceuticals, Inc. Fatty acid niacin conjugates and their uses
WO2012115695A1 (en) * 2011-02-25 2012-08-30 Catabasis Pharmaceuticals, Inc. Bis-fatty acid conjugates and their uses

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010002404A1 (en) * 1996-05-22 2001-05-31 Webb Nigel L. Fatty acid-pharmaceutical agent conjugates
US6919076B1 (en) * 1998-01-20 2005-07-19 Pericor Science, Inc. Conjugates of agents and transglutaminase substrate linking molecules
CA2351739A1 (en) * 1998-08-28 2000-03-09 Gryphon Sciences Polyamide chains of precise length, methods to manufacture them and their conjugates with proteins
US20100184730A1 (en) * 2008-07-08 2010-07-22 Vu Chi B Fatty Acid Acylated Salicylates and Their Uses
US20120184585A1 (en) * 2009-09-01 2012-07-19 Catabasis Pharmaceuticals, Inc. Fatty acid niacin conjugates and their uses
WO2011106688A1 (en) * 2010-02-26 2011-09-01 Catabasis Pharmaceuticals, Inc. Bis-fatty acid conjugates and their uses
WO2012115695A1 (en) * 2011-02-25 2012-08-30 Catabasis Pharmaceuticals, Inc. Bis-fatty acid conjugates and their uses

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FRED A. KUMMEROW: "The Synthesis of Long Chain Fatty Acid Derivatives of Pantothenic Acid1 Taketami Sakuragi", J. AM. CHEM. SOC., vol. 78, no. 4, 1956, pages 838 - 839 *

Also Published As

Publication number Publication date
WO2014068463A2 (en) 2014-05-08

Similar Documents

Publication Publication Date Title
WO2013175377A3 (en) Compositions and methods for treatment of mucositis
WO2014068463A3 (en) Compositions and methods for the treatment of inflammation and metabolic disorders
WO2013175376A3 (en) Compositions and methods for the treatment of local pain
PH12013500007A1 (en) Piperidine derivatives and their use for the treatment of metabolic disorders
WO2014174425A3 (en) Compositions and methods for the treatment of orthostasis and neurological diseases
WO2014087307A3 (en) Compositions and methods for the treatment of metabolic syndrome and diabetes
WO2016046680A3 (en) Compositions and methods for the treatment of liver metabolic diseases
WO2014091384A3 (en) Compositions and methods for the treatment of mucositis
WO2013175359A3 (en) Compositions and methods for the treatment of multiple sclerosis
WO2014087323A3 (en) Compounds and compositions for the treatment of autoimmune and chronic metabolic diseases
IN2014KN01113A (en)
WO2014080307A3 (en) Compositions and methods for the treatment of diabetes and pre-diabetes
WO2014006529A3 (en) Compositions and methods for the treatment of moderate to severe pain
WO2014106804A3 (en) Compositions and methods for the treatment of metabolic syndrome and diabetes
WO2014097137A3 (en) Compositions and methods for the treatment of seizures and neurologic diseases
WO2013167998A3 (en) Compositions and methods for the treatment of autonomic and other neurological disorders
WO2014195850A3 (en) Compositions and methods for the treatment of neurologic diseases and neurological disorders
WO2013175344A3 (en) Compositions and methods for treatment of peridontitis and rheumatoid arthritis
WO2013167989A3 (en) Compositions and methods for the treatment of neurological disorders
WO2014037834A3 (en) Compositions and methods for treatment of inflammation and lipid disorders
WO2014122621A3 (en) Compositions and methods for the treatment of metabolic conditions and neuromuscular diseases
WO2014037833A3 (en) Compositions and methods for treatment of inflammation and lipid disorders
WO2014118649A3 (en) Compositions and methods for the treatment of cardiovascular diseases
WO2014068459A3 (en) Compositions and methods for the treatment of pain and neurological diseases
WO2014068461A3 (en) Compositions and methods for the treatment of acute inflammation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13852160

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 13852160

Country of ref document: EP

Kind code of ref document: A2